While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...
On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...
Though Eli Lilly has shelved the obesity and T2D trial involving Zepbound, the US pharma will continue its obesity-only trial ...
The therapy demonstrated good tolerability across all assessed cohorts, with no reports of serious or severe treatment-emergent adverse events. Credit: PeopleImages / Shutterstock.com. SCYNEXIS has ...
Metsera said the Phase III trial should be initiated by the end of 2025. Image credit: Alones / Shutterstock.com. Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight ...
The intensity of TEAEs observed in the subjects during the treatment period was predominantly mild to moderate. Credit: Image Point Fr / Shutterstock.com. China Medical System and its subsidiary ...
ACL Digital will also be able to drive digital transformation for biotech, pharmaceutical and medical device companies. Credit: tilialucida / Shutterstock.com. ACL Digital has acquired US-based ...
Anebulo prioritised developing selonabant IV formulation as a potential treatment for paediatric patients with acute cannabis toxicity. Credit: murat photographer / Shutterstock.com. Anebulo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback